Premium
MMP9‐Responsive Peptides: Matrix Metalloproteinase‐9‐Responsive Surface Charge‐Reversible Nanocarrier to Enhance Endocytosis as Efficient Targeted Delivery System for Cancer Diagnosis and Therapy (Adv. Healthcare Mater. 9/2021)
Author(s) -
Han QiuJu,
Lan XiaoTong,
Wen Ying,
Zhang ChuanZeng,
Cleary Michael,
Sayyed Yasra,
Huang Guangdong,
Tuo Xiaoling,
Yi Long,
Xi Zhen,
Li LuYuan,
Zhang QiangZhe
Publication year - 2021
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.202170047
Subject(s) - nanocarriers , endocytosis , mmp9 , matrix metalloproteinase , in vivo , cancer therapy , nanoparticle , materials science , cancer research , nanotechnology , drug delivery , cancer , targeted therapy , surface charge , biophysics , medicine , chemistry , downregulation and upregulation , receptor , biochemistry , biology , microbiology and biotechnology , gene
In article number 2002143 by Qiang‐Zhe Zhang, Lu‐Yuan Li, and co‐workers, a novel MMP9‐catalyzed charge reversal nanoparticle (O‐NP) is developed for theranostic agents in cancer diagnosis and therapy. The O‐NP nanohybrid successfully performs preferential accumulation and enhances the endocytosis in MMP9‐expressing xenografted tumors by charge reversal from negative to positive in mouse models, which improves the sensitivity of diagnosis agents and the anti‐tumor effects of drugs in vivo by overcoming their low solubility and/or nonspecific enrichment.